Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)
| Status: | Archived |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Hospital |
| Therapuetic Areas: | Nephrology / Urology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2009 |
Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving CVVHD and/or ECMO
Critically ill patients with flu may receive a drug called oseltamivir. They may also
receive medical therapies to support their lung function (extracorporeal membrane
oxygenation; ECMO) and kidney function (continuous venovenous hemodialysis; CVVHD). CVVHD
and ECMO may remove some oseltamivir from the bloodstream. The purpose of this study is to
determine how much oseltamivir gets removed by CVVHD or ECMO in critically ill patients.
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health Systems The University of Michigan is home to one of the...
Click here to add this to my saved trials
